EVUSHELD
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
Conditions
COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
Trial Timeline
Aug 10, 2023 → Dec 22, 2023
NCT ID
NCT05569408About EVUSHELD
EVUSHELD is a pre-clinical stage product being developed by AstraZeneca for COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05569408. Target conditions include COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06156982 | Pre-clinical | Completed |
| NCT05465876 | Phase 2 | Withdrawn |
| NCT05569408 | Pre-clinical | Completed |
| NCT05712096 | Pre-clinical | Completed |
| NCT05667116 | Pre-clinical | Completed |
| NCT05663957 | Pre-clinical | Completed |
| NCT05461378 | Pre-clinical | Completed |
Competing Products
20 competing products in COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Human COVID-19 immunoglobulin (pH4) for intravenous injection + Placebo | Sinopharm | Phase 2 | 51 |
| Mavrilimumab + Placebos | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Gimsilumab + Placebo | Roivant Sciences | Phase 2 | 49 |
| Icosapent ethyl | Amarin Corporation | Phase 2 | 44 |
| Bamlanivimab + Placebo + Etesevimab | Eli Lilly | Phase 3 | 77 |
| Infliximab | Celltrion | Phase 2 | 52 |
| CT-P63 and CT-P66 / Placebo | Celltrion | Phase 3 | 77 |
| Enzalutamide Pill | Astellas Pharma | Phase 2 | 52 |
| S-892216 + Placebo | Shionogi | Phase 2 | 52 |
| S-892216 + Carbamazepine | Shionogi | Phase 1 | 33 |
| FOY-305 + Placebo | Ono Pharmaceutical | Phase 3 | 77 |
| Desidustat | Zydus Lifesciences | Phase 2 | 52 |
| LY3819253 + Placebo | Eli Lilly | Phase 1 | 33 |
| Bamlanivimab + Etesevimab + Placebo + VIR-7831 + Bebtelovimab | Eli Lilly | Phase 2 | 52 |
| Bamlanivimab | Eli Lilly | Phase 2 | 52 |
| LY3127804 + Placebo | Eli Lilly | Phase 2 | 52 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Bamlanivimab | Eli Lilly | Pre-clinical | 23 |
| LY3819253 + Placebo + Remdesivir | Eli Lilly | Phase 3 | 77 |
| LY3819253 + LY3832479 + LY3853113 + Placebo | Eli Lilly | Phase 2/3 | 65 |